Update On Phase 3 Librexia ACS Trial

Bristol-Myers Squibb Co BMY:

• UPDATE ON PHASE 3 LIBREXIA ACS TRIAL

• BRISTOL-MYERS SQUIBB CO - LIBREXIA ACS TRIAL DISCONTINUED DUE TO EFFICACY CONCERNS

• BRISTOL-MYERS SQUIBB CO - NO NEW SAFETY CONCERNS IDENTIFIED FOR MILVEXIAN

• BRISTOL-MYERS SQUIBB CO - LIBREXIA AF AND STROKE STUDIES CONTINUE, DATA EXPECTED 2026